On the 24th of April, 2017, PE HUB Network did a press release announcing Dr. Molly He as a venture partner with Foresite Capital. The press release highlights Dr. He’s extensive experience in pharmaceutical and genomic research. Specifically, it mentions her time at Illumina and Pacific Biosciences where she served in senior leadership positions directing improvements in protein reagent development. The release goes on to mention that Dr. He has a Bachelor’s degree in biochemistry from Nankai University and a Ph.D. in protein biophysics from the University of California, Los Angeles.http://www.insidermonkey.com/hedge-fund/foresite+capital/740/
Jim Tananbaum, M.D., CEO and Managing Director of Foresite Capital, gives Dr. Molly He high praise in the press release. He stated that “her extensive experience in genomics and drug development make her an invaluable resource to Foresite.” He also went on to cite her strong leadership skills. Foresite Capital provides capital and support to help companies with transformative products and services become healthcare leaders. Their focus is on the development and commercialization of transformative medical products that address critical healthcare needs.
Dr. Jim tananbaum founded Foresite Capital in 2011 with the aim to transform patient care. They are based in San Francisco, California. Since its founding, Foresite Capital has invested heavily in biotech and med tech companies both public and private. The firm has experienced a great deal of new IPO successes which include Juno Therapeutics and Bellicum Pharmaceuticals. Tananbaum believes the healthcare sector is experiencing unprecedented innovation. Foresite Capital has benefited a great deal by investing in the latest innovations in transformative health care. It can be argued that Foresite Capital’s ventures have also led to better patient outcomes.
Dr. Jim Tananbaum has over 25 years of experience in entrepreneurial healthcare investment. Prior to founding Foresite Capital he cofounded two successful biopharmaceutical companies. GelTex Pharmaceuticals and Theravance Inc. were both cofounded by Jim Tananbaum. Both companies were acquired and have a combined market capitalization of over $3 billion. Jim Tananbaum’s entrepreneurial success has landed him on Forbes’ Midas List of Top Tech Investors for the last 3 years. Tananbaum holds a B.S.E.E. from Yale University and an MD from Harvard Medical School. He also holds an MBA from Harvard Business School.
Follow him on Twitter